PATENT COOPERATION TREATY

From the INTERNATIONAL PRELIMINARY EXA	MINING AUTHORITY				9
To: GAL EHRLICH C/O ANTHONY CASTORINA			PCT	REC'D 13 F	EB 2006
2001 JEFFERSON DAVIS HIGHWAY SUITE 207			WRITTEN OPIN	WIPO	PC
ARLINGTON, VA 22202			(PCT Rule 66)	
		Date of Mailing (day/month/year)	08 FFR	2006	
Applicant's or agent's file reference			within 1 months/days		
01/22967	International filing date		the above date of mail Priority date (day/me	ing	
International application No.	_		' ` ` `	• ,	
International Patent Classification (IPC) of	17 December 2001 (17.) or both national classificat		19 December 2000 (19.12.2000)	
IPC(7): A01N 63/00; A61K 48/00; C12N 372			, 93.21, 93.7; 435/455,	320.1, 325, 363, 3	66,
Applicant INSIGHT STRATEGY AND MARKETI	NG LTD.				
IV Lack of unity of in V Reasoned stateme citations and expla VI Certain documents VII Certain defects in	ons relating to the following on the following of the fol	ing items: o novelty, inventive s with regard to novelt statement	tep and industrial appl	icability	у,
Authority to a How? By submitting For the form Also For an addition For the exam For an inform	limit indicated above. The grant an extension. See rugs a written reply, accompand the language of the accompand topportunity to subminer's obligation to considual communication with the	e applicant may, beforde 66.2(d). anied, where approprimendments, see Rules t amendments, see Rules der amendments and/o he examiner, see Rules	iate, by amendments, a s 66.8 and 66.9. ale 66.4. or arguments, see Rule s 66.6	according to Rule 6	
If no reply is filed, the interr 4. The final date by which the in examination report must be e Name and mailing address of the IPEA Mail Stop PCT, Atm: IPEA/ US	nternational preliminary stablished according to R		2003 (19.04.2003)	is of this opinion.	
Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	(Juang Nguyen, Telephone No. (Ph.D. 571) 272-1600	5'	

Form PCT/IPEA/408 (cover sheet)(July 1998)

International	application No.	

PCT/IL01/01169

I. B	asis of the op	inion
1. V	/ith regard to th	e elements of the international application:*
[the descri pages <u>1-4</u> pages NO	ational application as originally filed iption: 4, as originally filed, filed with the demand
í	pages NO	as originally filed ne, as amended (together with any statement) under Article 19 ne, filed with the demand ne, filed with the letter of
•	pages 1-4	, as originally filed NE, filed with the demand NE, filed with the letter of
,	pages <u>1</u> pages <u>NC</u> pages <u>NC</u>	ence listing part of the description:, as originally filed ONE, filed with the demand ONE, filed with the letter of
1	anguage in wh These element	the language, all the elements marked above were available or furnished to this Authority in the hich the international application was filed, unless otherwise indicated under this item. s were available or furnished to this Authority in the following language which is:
	the langu	tage of a translation furnished for the purposes of international search (under Rule23.1(b)). The translation of the international application (under Rule 48.3(b)). The translation furnished for the purposes of international preliminary examination (under Rules /or 55.3).
		any nucleotide and/or amino acid sequence disclosed in the international application, the written rawn on the basis of the sequence listing:
	contained filed toge furnished furnished The state internatio	d in the international application in printed form. ether with the international application in computer readable form. d subsequently to this Authority in written form. d subsequently to this Authority in computer readable form. ement that the subsequently furnished written sequence listing does not go beyond the disclosure in the onal application as filed has been furnished. ement that the information recorded in computer readable form is identical to the written sequence listing furnished.
4.		ndments have resulted in the cancellation of:
	tl tl tl tl this opinion beyond the	the description, pages NONE the claims, Nos. NONE the drawings, sheets/fig NONE the drawings, sheets/fig NONE to has been drawn as if (some of) the amendments had not been made, since they have been considered to go the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)). The supplemental Box (Rule 70.2(c)) the supplemental Box (Rule 70.2(c)
	opinion as "ori	

International application No.

PCT/IL01/01169

 The question whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of: the entire international application, claims Nos. 29-132 	
Claims Nos. <u>29-132</u>	
because:	
the said international application, or the said claim Nos relate to the following subject matter which does not require international preliminary examination (specify):	
the description, claims or drawings (indicate particular elements below) or said claims Nos are so unclear that no meaningful opinion could be formed (specify):	
the claims, or said claims Nos are so inadequately supported by the description that no meaningful opinion could be formed.	
no international search report has been established for said claims Nos. 1-132.	
2. A written opinion cannot be drawn due to the failure of the nucleotide and/or amino acid sequence listing to comply we the standard provided for in Annex C of the Administrative Instructions:	ith
the written form has not been furnished or does not comply with the standard.	
the computer readable form has not been furnished or does not comply with the standard.	

International application No. PCT/IL01/01169

ATEMENT		
Novelty (N)	Claims 1-28	YI
	Claims NONE	NC
- · · · · · · · · · · · · · · · · · · ·	China 100	YI
Inventive Step (IS)	Claims 1-28 Claims NONE	
	Claims NONE	···
Industrial Applicability (IA)	Claims 1-28	
	Claims NONE	N

Form PCT/IPEA/408 (Box V) (July 1998)

International application No.

PCT/IL01/01169

VIII. Certain observations on the international application

The following observations on the claims of the claims, description, and drawings or on the questions whether the claims are fully supported by the description, are made:

Claims 1-28 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because of the claims are not fully supported by the description. The description does not disclose the claimed invention in a manner sufficiently clear and complete for the claimed invention to be carried out by a person skilled in the art for the following reasons.

The instant claims encompass a stem cell preparation comprising stem cells coated and/or transfected with any exogenous extracellular matrix degrading enzyme, and a method of improving stem cell transplantation using the same. However, apart from the disclosure that human blood cord stem cells coating with heparanase improve transplantation in the NOD-SCID mouse model as reflected by the % of cells in the mouse bone marrow that express human CD45 and/or CD15 compared with the uncoated human blood cord stem cells, the instant application fails to provide sufficient guidance for a skilled artisan on how to obtain similar results using a stem cell preparation coating with any other exogenous extracellular matrix degrading enzymes (e.g., collagenase, elastase, trypsin, pepsin, cathepsins). It is also unclear whether the same effects could be obtained using a stem cell preparation transfected with a nucleic acid encoding for any exogenous extracellular matrix degrading enzyme, particularly whether the expression of an exogenous extracellular matrix degrading enzyme has any effect on the viability, proliferation and/or differentiation potentials of the transfected stem cells, and therefore the desired end-results contemplated by Applicants. Physiological art is recognized to be unpredictable. Therefore, with the lack of sufficient guidance provided by the instant disclosure, it would have required undue experimentation for a skilled artisan to make and use the present broadly claimed invention.

UMD	ITTEN	ואראוז

International application No. PCT/IL01/01169

Supplemental Box (To be used when the space in any of the preceding boxes is not sufficient)	
FIME LIMIT: The time limit set for response to a Written Opinion may not be extended. 37 CFR 1.484(d). Any response received after the expiration of the time limit set in the Written Opinion will not be considered in preparing the International Preliminary Examination Report.	
·	

Form PCT/IPEA/408 (Supplemental Box) (July 1998)